FNY Investment Advisers LLC purchased a new stake in shares of Immix Biopharma, Inc. (NASDAQ:IMMX – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 28,750 shares of the company’s stock, valued at approximately $63,000.
Separately, Geode Capital Management LLC boosted its position in Immix Biopharma by 5.6% during the 3rd quarter. Geode Capital Management LLC now owns 150,082 shares of the company’s stock valued at $224,000 after acquiring an additional 7,954 shares in the last quarter. 11.26% of the stock is owned by institutional investors.
Immix Biopharma Trading Up 1.0 %
Shares of Immix Biopharma stock opened at $2.02 on Thursday. Immix Biopharma, Inc. has a 12 month low of $1.26 and a 12 month high of $5.86. The firm has a market capitalization of $55.57 million, a P/E ratio of -2.38 and a beta of 0.27. The business has a fifty day simple moving average of $2.05 and a two-hundred day simple moving average of $1.95.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Immix Biopharma in a research report on Monday, January 6th.
Check Out Our Latest Report on Immix Biopharma
Immix Biopharma Profile
Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
Read More
- Five stocks we like better than Immix Biopharma
- The 3 Best Retail Stocks to Shop for in August
- 4 Social Media Stocks Set to Gain as TikTok Ban Looms
- What is the S&P 500 and How It is Distinct from Other Indexes
- How Do Stock Buybacks Affect Shareholders?
- What is the NASDAQ Stock Exchange?
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
Want to see what other hedge funds are holding IMMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immix Biopharma, Inc. (NASDAQ:IMMX – Free Report).
Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.